Neoadjuvant chemotherapy for advanced ovarian cancer: Overview of outcomes and unanswered questions

Expert Review of Anticancer Therapy

Volumn 11, Issue 7, 2011, Pages 1055-1069

  Onda, Takashi ^a   Yoshikawa, Hiroyuki ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

interval debulking surgery; neoadjuvant chemotherapy; optimal surgery; ovarian cancer; primary debulking surgery; prognosis; standard treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADENOCARCINOMA; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CYTODIAGNOSIS; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; HISTOPATHOLOGY; HUMAN; MORBIDITY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 79961062073     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.24     Document Type: Review

References (57)

1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst. Monogr. 42, 101-104 (1975).
2. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol. Oncol. 78(3 Pt 1), 269-274 (2000).
3. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin. Surg. Oncol. 19(1), 42-48 (2000). (Pubitemid 30439314)
4. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363(10), 943-953 (2010).
5. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 42(2), 146-150 (1991).
6. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur. J. Gynaecol. Oncol. 17(5), 393-396 (1996). (Pubitemid 26381529)
7. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol. Oncol. 72(1), 93-99 (1999). (Pubitemid 29045454)
8. Kayikçioǧlu F, Köse MF, Boran N, Çaliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 11(6), 466-470 (2001). (Pubitemid 34024805)
9. Vrščaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case- control study. Eur. J. Gynaecol. Oncol. 23(5), 405-410 (2002). (Pubitemid 35364667)
10. Morice P, Brehier-Ollive D, Rey A et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposednon- exposed study. Ann. Oncol. 14(1), 74-77 (2003). (Pubitemid 36150262)
11. Loizzi V, Cormio G, Resta L et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int. J. Gynecol. Cancer 15(2), 217-223 (2005). (Pubitemid 40396955)
12. Everett EN, French AE, Stone RL et al. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/ IV epithelial ovarian cancer. Am. J. Obstet. Gynecol. 195(2), 568-574; discussion 574-576 (2006).
13. Inciura A, Simavicius A, Juozaityte E et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer 6, 153 (2006).
14. Steed H, Oza AM, Murphy J et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int. J. Gynecol. Cancer 16(Suppl. 1), 47-53 (2006).
15. Hou JY, Kelly MG, Yu H et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol. Oncol. 105(1), 211-217 (2007). (Pubitemid 46441463)
16. Colombo PE, Mourregot A, Fabbro M et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur. J. Surg. Oncol. 35(2), 135-143 (2009).
17. Morice P, Dubernard G, Rey A et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg. 197(6), 955-963 (2003). (Pubitemid 38199555)
18. Kuhn W, Rutke S, Späthe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 92(10), 2585-2591 (2001). (Pubitemid 33049442)
19. Hegazy MA, Hegazi RA, Elshafei MA et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J. Surg. Oncol. 3, 57 (2005).
20. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J. Obstet. Gynaecol. Res. 32(1), 99-106 (2006).
21. Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur. J. Gynaecol. Oncol. 27(1), 25-28 (2006).
22. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol. Oncol. 103(3), 1070-1076 (2006). (Pubitemid 44821335)
23. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann. Surg. Oncol. 16(8), 2315-2320 (2009).
24. Kehoe S. Treatments for gynaecological cancers. Best Pract. Res. Clin. Obstet. Gynaecol. 20(6), 985-1000 (2006). (Pubitemid 44824844)
25. Onda T, Matsumoto K, Shibata T et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J. Clin. Oncol. 38(1), 74-77 (2008). (Pubitemid 351248124)
26. Onda T, Kamura T, Ishizuka N, Katsumata N, Fukuda H, Yoshikawa H. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J. Clin. Oncol. 34(1), 43-45 (2004). (Pubitemid 43115333)
27. Onda T, Kobayashi H, Nakanishi T et al. Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol. Oncol. 113(1), 57-62 (2009).
28. Kumar L, Hariprasad R, Kumar S et al. Neoadjuvant chemotherapy in advanced epithelial ovarian oancer (EOC): a Phase III randomized study. J. Clin. Oncol. (Meeting Abstracts) 24(18 Suppl.), 15000 (2006).
29. Kumar L, Hariprasad R, Kumar S et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): a prospective randomized study - interim results. J. Clin. Oncol. (Meeting Abstracts) 25(18 Suppl.), 5531 (2007).
30. Schwartz PE, Zheng W. Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol. Oncol. 90(3), 644-650 (2003).
31. Freedman OC, Dodge J, Shaw P et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecol. Oncol. 119(1), 22-25 (2010).
32. Donadio M, Bonardi G, Iberti V et al. The role of induction chemotherapy in inoperable ovarian cancer. Tumori 75(6), 609-614 (1989). (Pubitemid 20095049)
33. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol. Oncol. 37(3), 327-331 (1990). (Pubitemid 20182975)
34. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin. Oncol. (R. Coll. Radiol.) 5(4), 198-202 (1993). (Pubitemid 23271093)
35. Pölcher M, Mahner S, Ortmann O et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter Phase II trial (PRIMOVAR).Oncol. Rep. 22(3), 605-613 (2009).
36. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J. Clin. Oncol. 11(1), 166-172 (1993). (Pubitemid 23059991)
37. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101(2), 346-352 (2004). (Pubitemid 38890839)
38. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol. Oncol. 96(2), 301-306 (2005). (Pubitemid 40127125)
39. Vergote I, De Wever I, Tjalma W, van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 71(3), 431-436 (1998). (Pubitemid 29022333)
40. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16(Suppl. 1), 35-40 (2006).
41. Fagotti A, Ferrandina G, Fanfani F et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 13(8), 1156-1161 (2006). (Pubitemid 44337976)
42. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol. Oncol. 100(1), 33-37 (2006). (Pubitemid 41815046)
43. Aletti GD, Eisenhauer EL, Santillan A et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 120(1), 23-28 (2011).
44. Chi DS, Eisenhauer EL, Lang J et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 103(2), 559-564 (2006). (Pubitemid 44602167)
45. Eisenkop SM, Spirtos NM, Lin WC. 'Optimal' cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol. 103(1), 329-335 (2006). (Pubitemid 44389875)
46. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).Cancer 115(6), 1234-1244 (2009).
47. Aletti GD, Dowdy SC, Gostout BS et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107(1), 77-85 (2006).
48. Onda T, Yoshikawa H, Yasugi T, Matsumoto K, Taketani Y. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Jpn J. Clin. Oncol. 40(1), 36-41 (2010).
49. Mazzeo F, Berlierè M, Kerger J et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol. Oncol. 90(1), 163-169 (2003). (Pubitemid 37338092)
50. Le T, Faught W, Hopkins L, Fung Kee Fung M. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int. J. Gynecol. Cancer 15(5), 770-775 (2005). (Pubitemid 41783079)
51. Le T, Alshaikh G, Hopkins L, Faught W, Fung MF. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Ann. Surg. Oncol. 13(12), 1711-1716 (2006). (Pubitemid 44951481)
52. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol. Oncol. 88(1), 9-16 (2003). (Pubitemid 36062659)
53. Tiersten AD, Liu PY, Smith HO et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, Fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol. Oncol. 112(3), 444-449 (2009).
54. Elit L, Oliver TK, Covens A et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109(4), 692-702 (2007). (Pubitemid 46233230)
55. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374(9698), 1331-1338 (2009).
56. Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol. (Meeting Abstracts) 28(18 Suppl.), LBA1 (2010).
57. Pölcher M, Eckhardt M, Coch C et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol. 66(1), 203-207 (2010).